Andrx, Glaxo In New Row Over Wellbutrin

Law360, New York (December 20, 2005, 12:00 AM EST) -- Extending the drawn-out legal row over generic Wellbutrin, a subsidiary of Andrx Pharmaceuticals LLC has sued British rival GlaxoSmithKline PLC, alleging the company’s current formula for the antidepressant infringes Andrx’s patent.

The complaint, filed in the U.S. District Court for the Southern District of Florida, also names Glaxo subsidiary SmithKline Beecham Corp. It points to the defendant’s extended-release, 150 mg doses as the source of infringement.

Andrx applied for the patent in the case in May 2003, and it was issued in June 2005. It covers...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.